The estimated Net Worth of Anirvan Ghosh is at least 947 千$ dollars as of 2 August 2024. Dr Ghosh owns over 604 units of Unity Biotechnology Inc stock worth over 106,855$ and over the last 5 years he sold UBX stock worth over 81,525$. In addition, he makes 758,571$ as CEO & Director at Unity Biotechnology Inc.
Dr has made over 23 trades of the Unity Biotechnology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 604 units of UBX stock worth 924$ on 2 August 2024.
The largest trade he's ever made was selling 13,706 units of Unity Biotechnology Inc stock on 14 September 2022 worth over 6,579$. On average, Dr trades about 1,715 units every 23 days since 2020. As of 2 August 2024 he still owns at least 76,325 units of Unity Biotechnology Inc stock.
You can see the complete history of Dr Ghosh stock trades at the bottom of the page.
Dr. Anirvan Ghosh is the CEO & Director at Unity Biotechnology Inc.
As the CEO & Director of Unity Biotechnology Inc, the total compensation of Dr Ghosh at Unity Biotechnology Inc is 758,571$. There are 3 executives at Unity Biotechnology Inc getting paid more, with Keith Leonard having the highest compensation of 3,270,820$.
Dr Ghosh is 57, he's been the CEO & Director of Unity Biotechnology Inc since . There are 6 older and 16 younger executives at Unity Biotechnology Inc. The oldest executive at Unity Biotechnology Inc is David Lacey, 67, who is the Independent Director.
Anirvan's mailing address filed with the SEC is C/O UNITY BIOTECHNOLOGY, INC., 285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Unity Biotechnology Inc have traded over 9,012,473$ worth of Unity Biotechnology Inc stock and bought 3,200 units worth 28,480$ . The most active insiders traders include Kristina Burow、Robert Nelsen、Nathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of 65,316$. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth 236$.
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Unity Biotechnology Inc executives and other stock owners filed with the SEC include: